Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Christopher J. Hoimes

Hematology Oncology | Internal Medicine
Duke Health
Private Diagnostic Clinic PLLC
20 Duke Medicine Cir, Clinic 5 Cancer Center, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Duke Health
Private Diagnostic Clinic PLLC
20 Duke Medicine Cir, Clinic 5 Cancer Center, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Hoimes is an Internal Medicine provider in Durham, North Carolina. Dr. Hoimes is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, and Orchiectomy. Dr. Hoimes is currently accepting new patients.

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Internal Medicine
Licenses
Internal Medicine in OH
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Piedmont
  • HMO
  • POS
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Private Diagnostic Clinic PLLC
20 Duke Medicine Cir, Clinic 5 Cancer Center, Durham, NC 27710
Call: 919-684-8111
Other Locations
Private Diagnostic Clinic PLLC
2351 Erwin Rd, Durham, NC 27705
Call: 919-684-8111
Duke Health Integrated Practice Inc
2301 Erwin Rd, Durham, NC 27705
Call: 919-684-8111

Additional Areas of Focus

Dr. Hoimes has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Renal Cell Carcinoma (RCC)
Choriocarcinoma
Testicular Yolk Sac Tumor
Prostate Cancer
Bladder Cancer
Testicular Cancer
Urothelial Cancer
Chromophobe Renal Cell Carcinoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drugs: Bacillus of Calmette-Guerin, ALT-803
Study Phase: Phase 1/Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

71 Total Publications

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Journal: The oncologist
Published: June 09, 2025
View All 71 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Megan A. Mcnamara
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Megan A. Mcnamara
Hematology Oncology | Oncology | Hematology

Rex Hospital Inc

300 Health Park Dr, Suite 220, 
Garner, NC 
 (29.8 miles away)
919-250-5955
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Megan Mcnamara is a Hematologist Oncology specialist and an Oncologist in Garner, North Carolina. Dr. Mcnamara is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Relapsed Refractory Multiple Myeloma (RRMM). Dr. Mcnamara is currently accepting new patients.

Robin L. Hardie
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Robin L. Hardie
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Robin L. Hardie
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Experience:
27+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robin Hardie is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Hardie has been practicing medicine for over 27 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), Familial Colorectal Cancer, and Colorectal Cancer.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Peter R. Ennever
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Peter R. Ennever
Hematology Oncology | Hematology | Oncology

The Moses H Cone Memorial Hospital Operating Corporation

2630 Willard Dairy Rd, Suite 300, 
High Point, NC 
 (57.6 miles away)
336-884-3888
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Ennever is a Hematologist Oncology specialist and a Hematologist in High Point, North Carolina. Dr. Ennever is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Antiphospholipid Syndrome, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Myelodysplastic Syndrome (MDS). Dr. Ennever is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoimes's expertise for a condition
ConditionClose
  • Elite
  • Urothelial Cancer
    Dr. Hoimes is
    Elite
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Distinguished
  • Bladder Cancer
    Dr. Hoimes is
    Distinguished
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Hoimes is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Muscle Invasive Bladder Cancer
    Dr. Hoimes is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Prostate Cancer
    Dr. Hoimes is
    Distinguished
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Hoimes is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Hoimes is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Non-Muscle Invasive Bladder Cancer
    Dr. Hoimes is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Hoimes is
    Advanced
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • Wilms Tumor
    Dr. Hoimes is
    Advanced
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • Experienced
  • Adrenocortical Carcinoma
    Dr. Hoimes is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Hoimes is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Choriocarcinoma
    Dr. Hoimes is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Classical Hodgkin Lymphoma
    Dr. Hoimes is
    Experienced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Lung Adenocarcinoma
    Dr. Hoimes is
    Experienced
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Lung Cancer
    Dr. Hoimes is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved